Boobalan Pachaiyappan

Brandon Folkes

David Hoang

Scott Henry

Robert Hazlett

Matthew Kaplan

Matt Kaplan

- **RedHill Biopharma Ltd.** has signed a new Middle East licensing deal for its drug **Talicia®**, with a potential value of **$1.8 million plus sales royalty payments**.  **[1553846_0001178913-25-003471_zk2533838.htm:1]** 
- The agreement includes **$500,000 in guaranteed payments**, consisting of a **$250,000 upfront payment** and **$250,000 in fixed payments due within 18 months**.  **[1553846_0001178913-25-003471_zk2533838.htm:1]** 
- RedHill may also receive a minimum of **$1.3 million in near-term potential milestone payments** and tiered royalties up to mid-teens percent on Talicia net sales.  **[1553846_0001178913-25-003471_zk2533838.htm:1]** 
- This deal is intended to accelerate Talicia’s entry into new Middle East markets.  **[1553846_0001178913-25-003471_zk2533838.htm:0]**

RedHill Biopharma Signs New Middle East Deal for Talicia

- The New York Supreme Court has upheld its original summary judgment ruling in favor of RedHill Biopharma Ltd. against Kukbo Co. Ltd., unequivocally dismissing Kukbo's defense and confirming RedHill's fulfillment of agreement obligations.  **[1553846_0001178913-25-003401_zk2533819.htm:1]** 
- RedHill Biopharma has been granted approximately **$10 million in total awards**, which includes an **$8.25 million original award** and a subsequent **$1.82 million award** for legal costs and expenses, along with 9% statutory interest accrual.  **[1553846_0001178913-25-003401_zk2533819.htm:1]** 
- Kukbo Co. Ltd. retains the right to further appeal the Court's ruling.  **[1553846_0001178913-25-003401_zk2533819.htm:1]** 
- In addition to the New York Supreme Court case, RedHill Biopharma recently secured an attachment grant against Kukbo from Korea's Incheon District Court, allowing for a court-ordered seizure of Kukbo's assets.  **[1553846_0001178913-25-003401_zk2533819.htm:1]**

RedHill Biopharma (RDHL)